.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Army
Fish and Richardson
Mallinckrodt
Julphar
Chubb
Argus Health
Federal Trade Commission
US Department of Justice
Novartis

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,388,134

« Back to Dashboard

Which drugs does patent 9,388,134 protect, and when does it expire?


Patent 9,388,134 protects ENTRESTO and is included in one NDA.

This patent has forty-eight patent family members in thirty countries.

Summary for Patent: 9,388,134

Title:Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Inventor(s): Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Blacklock; Thomas J. (East Hanover, NJ), Karpinski; Piotr Henryk (Lincoln Park, NJ)
Assignee: NOVARTIS, AG (Basel, CH)
Application Number:14/311,788
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-001Jul 7, 2015RXYesNo► Subscribe► SubscribeTREATMENT OF HEART FAILURE► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-002Jul 7, 2015RXYesNo► Subscribe► SubscribeTREATMENT OF HEART FAILURE► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-003Jul 7, 2015RXYesYes► Subscribe► SubscribeTREATMENT OF HEART FAILURE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,388,134

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,938Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,388,134

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2459809► Subscribe
Russian Federation2007123671► Subscribe
Portugal1948158► Subscribe
Peru08032007► Subscribe
New Zealand600626► Subscribe
New Zealand594006► Subscribe
Norway2016008► Subscribe
Norway340315► Subscribe
Norway20151656► Subscribe
Norway337288► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Julphar
Chubb
Mallinckrodt
Chinese Patent Office
Baxter
QuintilesIMS
Cantor Fitzgerald
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot